Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.

Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. A new wave of value and ...

Eli Lilly is beefing up muscle health R&D, ... Ph.D., chief scientific officer at Lilly, discussed what Lilly wants to see from muscle-boosting drugs on an earnings call in February.

Lilly is expected to post earnings of $5.56 per share for the current quarter, representing a year-over-year change of +41.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.